Subcutaneous Epcoritamab in Combination with R2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial

KM Linton; Björn E. Wahlin; S Leepa; Franck Morschhauser; B Elliot; T Liu; MC Stirner; A Abbas; L Falchi

doi:10.1182/blood-2021-146629

Subcutaneous Epcoritamab in Combination with R2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial

KM Linton, Björn E. Wahlin, S Leepa, Franck Morschhauser, B Elliot, T Liu, MC Stirner, A Abbas, L Falchi

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	5
Journal	Blood
Volume	138
DOIs	https://doi.org/10.1182/blood-2021-146629
Publication status	Published - 23 Nov 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2021-146629

Cite this

@article{05692556d35f4e5d92ce26090b0ec23a,

title = "Subcutaneous Epcoritamab in Combination with R2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial",

author = "KM Linton and Wahlin, {Bj{\"o}rn E.} and S Leepa and Franck Morschhauser and B Elliot and T Liu and MC Stirner and A Abbas and L Falchi",

year = "2021",

month = nov,

day = "23",

doi = "10.1182/blood-2021-146629",

language = "English",

volume = "138",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Subcutaneous Epcoritamab in Combination with R2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma

T2 - Preliminary Results from a Phase 1/2 Trial

AU - Linton, KM

AU - Wahlin, Björn E.

AU - Leepa, S

AU - Morschhauser, Franck

AU - Elliot, B

AU - Liu, T

AU - Stirner, MC

AU - Abbas, A

AU - Falchi, L

PY - 2021/11/23

Y1 - 2021/11/23

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000736413906102&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1182/blood-2021-146629

DO - 10.1182/blood-2021-146629

M3 - Meeting Abstract

SN - 0006-4971

VL - 138

JO - Blood

JF - Blood

ER -

Subcutaneous Epcoritamab in Combination with R2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial

UN SDGs

Access to Document

Other files and links

Cite this